Browse the evidence

Adopting MLCDs, particularly those with sufficient fiber content, can reduce the risk of cardiovascular diseases in patients suffering from dyslipidemia.

Practitioners may consider recommending MLCDs with sufficient fiber to patients with dyslipidemia to help reduce cardiovascular risks.

Personalized nutrition (PN) interventions can improve eating behavior with potential to improve health.

Practitioners should consider implementing personalized nutrition strategies to enhance dietary adherence and health outcomes.

The diet beneficially altered microbiota-derived plasma metabolites implicated in chronic non-communicable diseases.

Practitioners may consider the impact of dietary choices on metabolites that influence chronic disease risk.

Resmetirom has shown positive effects regarding CVD risk in the context of MASLD treatment.

Consider resmetirom as a potential treatment option for patients with MASLD at risk for CVD.

Tirzepatide was evaluated for its effects on cardiovascular and diabetic kidney disease biomarkers in overweight and obese adults with type 1 diabetes over a period of 21 months.

Practitioners may consider tirzepatide for managing cardiovascular and kidney health in overweight and obese patients with type 1 diabetes.

Both IF and KD enhance insulin sensitivity, promote autophagy, reduce inflammation, and activate energy-regulating pathways (AMPK) while inhibiting mTOR.

Understanding these mechanisms can help practitioners explain the benefits of IF and KD to patients.

Higher ultraprocessed grain intake is associated with increased risk of developing inflammatory bowel disease (IBD), with participants consuming ≥19 g/d having a hazard ratio (HR) of 1.86 compared to those consuming <9 g/d.

Practitioners should advise minimizing ultraprocessed grain consumption to reduce IBD risk.

Participants with greater ultraprocessed food intake (≥5 servings per day) are linked to a higher risk of developing IBD, with a hazard ratio of 3.95 compared to those consuming <1 serving per day.

Reducing ultraprocessed food intake may lower the risk of IBD.

The FDA has conditionally approved Resmetirom as the first pharmacological treatment for MASH.

Clinicians should consider Resmetirom as a treatment option for MASH.

Recent innovations in bariatric research include pharmacological therapies targeting GLP-1 receptors, minimally invasive procedures, and genetic and microbiome-based strategies.

These innovations may provide new options for obesity treatment.

Pharmacoeconomic analyses support the cost-effectiveness of combining behavioral, pharmacological, and surgical modalities for obesity treatment.

Integrating various treatment modalities can enhance cost-effectiveness in obesity management.

Plant-based diets improve cardiovascular health by modulating gut microbiota and metabolites.

Practitioners may consider recommending plant-based diets for cardiovascular health.

GLP-1 receptor agonists and dual incretin agonists provide clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.

Practitioners can consider GLP-1 receptor agonists and dual agonists as effective options for managing weight and cardiovascular health in patients with T2DM and obesity.

Consumption of ultra-processed foods (UPFs) is associated with increased cardiovascular (CV) risk.

Clinicians should consider the impact of UPFs when advising patients on cardiovascular health.

Obesity and diabetes mellitus are major risk factors for the development and progression of chronic kidney disease (CKD).

Healthcare providers should prioritize screening for CKD in patients with obesity and diabetes.

Excessive consumption of industrial seed oils rich in linoleic acid contributes to mitochondrial dysfunction.

Reducing intake of linoleic acid-rich oils may be beneficial for mitochondrial health.

Higher adipose tissue GIP receptor mRNA expression is related to elevated glycerol release after GIP and GLP-1/GIP/glucagon receptor triagonist stimulation.

Increased GIP receptor expression may enhance fat mobilization, suggesting a focus for obesity treatments.

BGM1812 is a novel dual amylin and calcitonin receptor agonist with enhanced efficacy compared to petrelintide.

BGM1812 may be a promising option for obesity treatment.

BGM1812 exhibits excellent performance in terms of half-life, stability, and solubility.

These properties suggest BGM1812 could be a viable therapeutic option.

The interaction between hyperglycemia, endothelial dysfunction, inflammation, and thrombosis contributes to the progression of coronary artery disease (CAD) and its acute complications.

Understanding these interactions can help in developing targeted therapies for CAD.

GLP-1 receptor agonist patients had significantly lower serum albumin (4.06 g/dL) and prealbumin levels (23.52 mg/dL) compared to controls (4.22 g/dL and 25.55 mg/dL, respectively).

Monitoring nutritional status, including serum albumin and prealbumin, may be important for patients on GLP-1 receptor agonists.

Rational protein engineering and delivery innovations transformed incretin biology into global metabolic therapeutics.

Innovations in protein engineering can enhance therapeutic efficacy.

Genetic variation within the leptin-melanocortin pathway may predict response to endoscopic interventions and guide personalized treatment selection.

Understanding genetic factors can help tailor obesity treatments to individual patients.

The use of nano-based medications through transdermal delivery is important for effective obesity treatment.

Practitioners should consider incorporating nano-based medications for better treatment outcomes.